Lexicon Pharmaceuticals (LXRX) Gains from Investment Securities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 11 years of Gains from Investment Securities data on file, last reported at $2.8 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $2.8 million, up 397.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (up 446.55% YoY), and the FY2025 annual result was $1.7 million, changed N/A from the prior year.
• Gains from Investment Securities grew to $2.8 million in Q1 2026 per LXRX's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $2.8 million in Q1 2026 and troughed at -$5.2 million in Q4 2022.
• A 5-year average of $20300.0 and a median of $526500.0 in 2024 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 399.32% in 2025 and fell as far as 403.12% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at -$5.2 million in 2022, then jumped by 115.83% to $824000.0 in 2023, then plunged by 41.63% to $481000.0 in 2024, then sank by 403.12% to -$1.5 million in 2025, then jumped by 294.99% to $2.8 million in 2026.
• Business Quant data shows LXRX's Gains from Investment Securities at $2.8 million in Q1 2026, -$1.5 million in Q4 2025, and $2.6 million in Q3 2025.